Finance

Lists
MNPR:NASDAQ
Monopar Therapeutics Inc
$111.93
+0.04%
(+0.040) 1D
$111.50
-0.38% (-0.43)
After hours
Closed: Aug 31, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MNPR...
Open
$110.70
High
$112.96
Low
$106.67
Mkt. cap
751.29M
Avg. vol.
261.70K
Volume
141.85K
52-wk high
$124.42
52-wk low
$32.77
EPS
-$2.17
Beta
1.47
Shares outstanding
6.71M
No. of employees
22
Open
$110.70
High
$112.96
Low
$106.67
Mkt. cap
751.29M
Avg. vol.
261.70K
Volume
141.85K
52-wk high
$124.42
52-wk low
$32.77
EPS
-$2.17
Beta
1.47
Shares outstanding
6.71M
No. of employees
22
News stories
From web sources and news partners
About Monopar Therapeutics Inc
CEO-
Employees22
Founded2014
HeadquartersWilmette, Illinois, United States
SectorBiotechnology
Websitemonopartx.com
Analyst ratings
Based on 8 analysts giving stock ratings to MNPR in the past 3 months
Strong buy
Buy
7
Hold
1
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for MNPR in the last 3 months.
Highest
Current $111.93
$133.00 (+18.82%)
Average
$121.13 (+8.22%)
Lowest
$101.00 (-9.77%)
Analyst
Recommendation
Action
Price target
Projected
Date
Maxwell Skor
Morgan Stanley
Buy
Reiterated
$130.00
+16.1%
08/17/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
$125.00
+11.7%
08/13/2026
Kristen Kluska
Cantor Fitzgerald
Hold
Downgraded
$119.00
+6.3%
08/12/2026
Etzer Darout
Barclays
Buy
Maintained
$128.00
+14.4%
08/13/2026
Boris Peaker
JonesTrading
Buy
Maintained
$130.00
+16.1%
08/12/2026
Jeet Mukherjee
BTIG
Buy
Maintained
$133.00
+18.8%
08/12/2026
Chad Messer
Lake Street
Buy
Maintained
$103.00
-8%
06/30/2026
Biren Amin
Piper Sandler
Buy
Maintained
$101.00
-9.8%
06/29/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
$115.00
+2.7%
05/15/2026
Soumit Roy
JonesTrading
Buy
Maintained
$130.00
+16.1%
04/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
2.59M
3.94M
3.49M
4.77M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.50M
2.21M
1.74M
1.88M
Operating expense
4.09M
6.16M
5.23M
6.64M
Total operating expenses
4.09M
6.16M
5.23M
6.64M
Operating income
-4.09M
-6.16M
-5.23M
-6.64M
Other non operating income
1.00
-1.00
-
32.16K
EBT including unusual items
-3.44M
-5.20M
-3.89M
-5.31M
EBT excluding unusual items
-3.44M
-5.20M
-3.89M
-5.31M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-3.44M
-5.20M
-3.89M
-5.31M
Net profit margin
-
-
-
-
Earnings per share
-0.48
-0.61
-0.46
-0.62
Interest and investment income
655.47K
954.43K
1.33M
1.30M
Interest expense
-
-
-
-
Net interest expenses
655.47K
954.43K
1.33M
1.30M
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps